Reaffirming their commitment to actively engage patients in regulatory decisions on drug approvals, the FDA held its first Patient Engagement Advisory Committee meeting on October 11.
Reaffirming their commitment to actively engage patients in regulatory decisions on drug approvals, the FDA held its first Patient Engagement Advisory Committee (PEAC) meeting on October 11.
PEAC includes 9 core voting members who are selected by the FDA Commissioner Scott Gottlieb, MD, or designated from among experts who are knowledgeable in areas such as clinical research, primary care patient experience, and healthcare needs of patient groups in the United States, according to information provided on the FDA’s website.
A statement released by Gottlieb says, “involving the end-user—the patient—in identifying health priorities and outcomes desired from health interventions is critically important.” Achieving this objective necessitates patient input at each stage of a drug product or device development life cycle. Yesterday’s meeting was focused on engaging patients in different aspects of the clinical trial process: trial design, recruitment, enrollment, and retention. Additionally, the FDA is also seeking patient input on FDA communication of clinical trial results.
PEAC was founded by the FDA’s Center for Devices and Radiological Health (CDRH), which has led the development of patient preference studies and incorporation of patient-reported outcome (PRO) measures in numerous devices. Additionally, CDRH has worked to collect real-world evidence that can inform the regulatory decision-making process. Their guidance provides stakeholders to leverage information from electronic health records, insurance claims databases, and registries to facilitate more efficient regulatory decisions for medical devices.
Gottlieb’s statement points out that patients, through novel registry platforms that collect trackable patient information, are spearheading the real-world data collection. “We’re fostering interactions with these patient-led registries to help them become vehicles for regulatory change,” he notes.
The statement emphasizes the importance of patient input, in the form of health data gathered from patient reports, in evaluating the probable benefit of a device: “The FDA can also consider rigorous, systematically gathered patient preference information as a part of the totality of the evidence from clinical and nonclinical testing,” Gottlieb says, adding that PEAC members will help develop the parameters on identifying the appropriate standards and criteria.
Gottlieb notes that efforts across the various divisions within the FDA will build on the CDRH efforts, including the creation of a team to coordinate agency-wide and multi-center projects related to patient engagement. With these initial steps, the FDA hopes to create a consistent approach for using PRO tools across the agency.
“This new patient affairs team is one reflection of our commitment to the goal of elevating the patient role in our work. The advisory committee that we’re inaugurating today is another measure of that promise,” Gottlieb states.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More